-+ 0.00%
-+ 0.00%
-+ 0.00%

NORTHSTRIVE BIOSCIENCES INC. SCHEDULES PRE-IND MEETING WITH FDA FOR EL-22, AN OBESITY THERAPY TARGETING FAT LOSS AND MUSCLE PRESERVATION IN COMBINATION WITH GLP-1

Reuters·03/10/2025 12:00:44

Please log in to view news